Published in BJOG on January 15, 2013
Standardised Registration of Surgical Complications in Laparoscopic-Gynaecological Therapeutic Procedures Using the Clavien-Dindo Classification. Geburtshilfe Frauenheilkd (2014) 0.81
Bleomycin sclerotherapy for severe symptomatic and persistent pelvic lymphocele. Case Rep Obstet Gynecol (2014) 0.75
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene (2006) 2.05
p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet (1995) 1.84
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol (2010) 1.59
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res (2001) 1.59
p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol (1999) 1.45
Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene (2007) 1.37
p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res (1998) 1.13
CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther (2003) 1.09
Cardiac function estimation from MRI using a heart model and data assimilation: advances and difficulties. Med Image Anal (2006) 1.05
Diffusion-weighted imaging (DWI) in MR mammography (MRM): clinical comparison of echo planar imaging (EPI) and half-Fourier single-shot turbo spin echo (HASTE) diffusion techniques. Eur Radiol (2009) 1.05
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer (2000) 1.04
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer (1999) 1.03
Surgical management of multiple bilateral fibroadenoma of the breast: the Ribeiro technique modified by Rezai. Anticancer Res (2009) 1.00
A geographical approach to identify sleeping sickness risk factors in a mangrove ecosystem. Trop Med Int Health (2010) 0.98
Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients. Anticancer Res (1998) 0.97
Health seeking behaviour and household health expenditures in Benin and Guinea: the equity implications of the Bamako Initiative. Int J Health Plann Manage (1997) 0.95
Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther (2001) 0.94
p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology (1999) 0.94
Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin. Int J Cancer (1998) 0.93
Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res (2000) 0.91
Clinical MR mammography: impact of hormonal status on background enhancement and diagnostic accuracy. Rofo (2011) 0.91
Simulation of cardiac pathologies using an electromechanical biventricular model and XMR interventional imaging. Med Image Anal (2005) 0.89
Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer (2005) 0.88
Laparascopically assisted vaginal resection of rectovaginal endometriosis. Obstet Gynecol (2000) 0.87
Chicken ovalbumin upstream promoter transcription factor (COUP-TF): an orphan steroid receptor with a specific pattern of differential expression in human ovarian cancer cell lines. Gynecol Oncol (1993) 0.86
Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol (2013) 0.86
Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma. J Cancer Res Clin Oncol (2011) 0.86
Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines. Anticancer Res (1997) 0.85
[Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology]. Zentralbl Gynakol (2001) 0.84
Chicken ovalbumin upstream promoter--transcription factor (COUP-TF) expression in human endometrial cancer cell lines. Anticancer Res (1997) 0.83
Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. Gynecol Oncol (2006) 0.83
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Hum Gene Ther (2001) 0.83
Understanding the mechanisms amenable to CRT response: from pre-operative multimodal image data to patient-specific computational models. Med Biol Eng Comput (2013) 0.83
Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol (2014) 0.82
Heterogeneity of circulating epithelial tumour cells from individual patients with respect to expression profiles and clonal growth (sphere formation) in breast cancer. Ecancermedicalscience (2013) 0.82
Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. Clin Cancer Res (1997) 0.82
Treatment of endometriosis of uterosacral ligament and rectum through the vagina: description of a modified technique. Hum Reprod (2009) 0.82
Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study. Cancer Chemother Pharmacol (2009) 0.81
Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol (2001) 0.81
Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br J Cancer (1999) 0.81
Venous coupler for free-flap anastomosis. Anticancer Res (2009) 0.81
Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients. Int J Mol Med (2000) 0.80
Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients. Cancer Epidemiol Biomarkers Prev (1995) 0.80
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol (2002) 0.80
A systematic comparison of two pulse sequences for edema assessment in MR-mammography. Eur J Radiol (2011) 0.78
Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors. Ann Oncol (2008) 0.78
Affordability, cost-effectiveness and efficiency of primary health care: the Bamako Initiative experience in Benin and Guinea. Int J Health Plann Manage (1997) 0.78
Toward integrated management of cerebral aneurysms. Philos Trans A Math Phys Eng Sci (2010) 0.78
Potential of MR mammography to predict tumor grading of invasive breast cancer. Rofo (2011) 0.77
Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology. Gynecol Oncol (2009) 0.77
Sentinel lymph node biopsy in vulvar cancer: a pilot study. Eur J Gynaecol Oncol (2009) 0.77
Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL). Anticancer Res (1994) 0.77
[Vulvodynia]. Hautarzt (2005) 0.77
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol (2006) 0.76
Value of ductal obstruction sign in the differentiation of benign and malignant breast lesions at MR imaging. Eur J Radiol (2009) 0.75
[Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression]. Geburtshilfe Frauenheilkd (1995) 0.75
Can color-coded parametric maps improve dynamic enhancement pattern analysis in MR mammography? Rofo (2009) 0.75
[Choriocarcinoma]. Rofo (2006) 0.75
Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro. J Cancer Res Clin Oncol (2000) 0.75
Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples. Oncol Rep (1998) 0.75
[Possibilities and limits of mammography with special reference to breast carcinoma--a comparison of clinical, mammography and histologic diagnoses]. Zentralbl Gynakol (1997) 0.75
Modulation of soluble CD44 concentrations by hormone and anti-hormone treatment in gynecological tumor cell lines. Oncol Rep (2001) 0.75
Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma. J Cancer Res Clin Oncol (2007) 0.75
[Intraluminal hypertension as a pathogenetic factor of acute pancreatitis in the rat (author's transl)]. Z Gastroenterol (1980) 0.75
[Space-occupying tumor of the temporal region with facial nerve palsy, vestibular dysfunction and hearing loss]. HNO (2011) 0.75
[Results of conservative surgery in cancer of the rectum]. Tunis Med (1991) 0.75
Intron 9 retention in gene transcripts suggests involvement of CD44 in the tumorigenesis of ovarian cancer. Anticancer Res (1998) 0.75
Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives. Anticancer Res (1997) 0.75